Skip to content

Pelthos Therapeutics Inc.: 10-Q filed 2024-08-13

What Pelthos Therapeutics Inc. reported in its quarterly report filed 2024-08-13 (fiscal Q2 2024): 24 published measures, 70 facts as tagged in accession 0001753926-24-001423.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-13
Fiscal period
fiscal Q2 2024
Accession
0001753926-24-001423 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Pelthos Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-302,603,600USD
At 2023-12-3196,391USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-302,786,121USD
At 2023-12-316,540,943USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-182,521USD
At 2024-03-311,130,120USD
At 2023-12-31-6,444,552USD
At 2023-06-30-4,900,886USD
At 2023-03-31-4,440,877USD
At 2022-12-31-3,706,537USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-12-31100,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1,771,619USD91
2024-01-01 to 2024-06-30-4,333,949USD182
2024-01-01 to 2024-03-31-2,562,330USD91
2023-04-01 to 2023-06-30-953,347USD91
2023-01-01 to 2023-06-30-1,919,908USD181
2023-01-01 to 2023-03-31-966,561USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-4,944,308USD182
2023-01-01 to 2023-06-30-366,989USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-307,253,015USD182
2023-01-01 to 2023-06-30393,808USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-17,853,598USD
At 2023-12-31-13,519,649USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-305,773,708shares91
2024-01-01 to 2024-06-305,232,349shares182
2023-04-01 to 2023-06-301,002,779shares91
2023-01-01 to 2023-06-301,056,646shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.31USD/shares91
2024-01-01 to 2024-06-30-0.83USD/shares182
2023-04-01 to 2023-06-30-0.95USD/shares91
2023-01-01 to 2023-06-30-1.82USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-06-30751,530USD182
2023-01-01 to 2023-06-30599,559USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1,764,086USD91
2024-01-01 to 2024-06-30-3,698,068USD182
2023-04-01 to 2023-06-30-777,160USD91
2023-01-01 to 2023-06-30-1,691,743USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-302,603,600USD
At 2023-12-3196,391USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-302,786,121USD
At 2023-12-316,540,943USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,764,086USD91
2024-01-01 to 2024-06-303,698,068USD182
2023-04-01 to 2023-06-30777,160USD91
2023-01-01 to 2023-06-301,691,743USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-04-01 to 2024-06-3012,955USD91
2024-01-01 to 2024-06-30479,561USD182
2023-04-01 to 2023-06-3049,955USD91
2023-01-01 to 2023-06-30236,072USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-305,823,166shares
At 2023-12-313,906,300shares
At 2022-08-101,187,302shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-302,405,098USD
At 2023-12-3196,391USD
At 2023-06-3081,893USD
At 2022-12-3155,074USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-3017,670,493USD
At 2023-12-317,074,646USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2022-08-1044,800,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-06-30363,429USD
At 2023-12-31645,947USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,209,874USD91
2024-01-01 to 2024-06-301,997,435USD182
2023-04-01 to 2023-06-30537,876USD91
2023-01-01 to 2023-06-301,015,506USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-7,533USD91
2024-01-01 to 2024-06-30-635,881USD182
2023-04-01 to 2023-06-30-176,187USD91
2023-01-01 to 2023-06-30-228,165USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-01-01 to 2024-06-305,972,000USD182

Inspect the source

Entity
Pelthos Therapeutics Inc. / CIK 0001919246
Captured
2026-09-21T17:41:05.640Z
SEC response SHA-256
bebd759cb155e6f159380f827fde1eb11645fa7d73c4afdb0e369eaa80f099b9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001919246.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))